Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease.
Expression of nitric oxide synthase (NOS) mRNA in post mortem brain was studied in putamen, globus pallidus and subthalamic nucleus (STN) of neurologically normal control subjects and patients with Parkinson's disease (PD) using in situ hybridization histochemistry. In PD, a significant increase in NOS mRNA expression was observed in the dorsal two-thirds of the STN with respect to the ventral one-third of the STN. A significant increase in NOS mRNA expression per cell in the medial medullary lamina of the globus pallidus was also observed in PD. NOS mRNA expression was significantly reduced in PD putamen. These findings provide evidence of increased activity of STN neurotransmitter systems in PD and demonstrate for the first time in any species that basal ganglia nitric oxide systems can be selectively regulated in response to changes in dopaminergic input.
Eve
D J
DJ
Parkinson's Disease Society, Brain Research Centre (Brain Bank), 1 Wakefield Street, London WC1N 1PJ, UK.
Nisbet
A P
AP
Kingsbury
A E
AE
Hewson
E L
EL
Daniel
S E
SE
Lees
A J
AJ
Marsden
C D
CD
Foster
O J
OJ
D000368:Aged; D000369:Aged, 80 and over; D001479:Basal Ganglia / Q000201:enzymology*; D002102:Cadaver; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D019001:Nitric Oxide Synthase / Q000235:genetics*; D052248:Nitric Oxide Synthase Type I; D010300:Parkinson Disease / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis
D012333:RNA, Messenger; C496320:NOS1 protein, human; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I